Circulating Soluble EPCR Levels Are Reduced in Patients with Ischemic Peripheral Artery Disease and Associated with Markers of Endothelial and Vascular Function

(1) Background: Endothelial dysfunction initiates cardiovascular pathologies, including peripheral artery disease (PAD). The pathophysiology of impaired new vessel formation in the presence of angiogenic stimuli, such as ischemia and inflammation, is unknown. We have recently shown in mice that reduced endothelial protein C receptor (EPCR) expression results in defective angiogenesis following experimental hindlimb ischemia. (2) Purpose: To determine soluble (s)EPCR levels in the plasma of patients with PAD and to compare them with the protein C activity and biomarkers of endothelial function, inflammation, and angiogenesis. (3) Methods and Results: Clinical tests of vascular function and immunoassays of plasma from patients with PAD stage II were compared to age- and sex-matched individuals with and without cardiovascular risk factors or PAD stage III/IV patients. sEPCR levels were significantly lower in PAD stage II patients compared to subjects with risk factors, but no PAD, and further decreased in PAD stage III/IV patients. Plasma protein C activity or levels of ADAM17, a mediator of EPCR shedding, did not differ. Significant associations between sEPCR and the ankle-brachial index (p = 0.0359), age (p = 0.0488), body mass index (p = 0.0110), and plasma sE-selectin levels (p = 0.0327) were observed. High-sensitive CRP levels and white blood cell counts were significantly elevated in PAD patients and associated with serum glucose levels, but not sEPCR. In contrast, plasma TNFα or IL1β levels did not differ. Circulating levels of VEGF were significantly elevated in PAD stage II patients (p = 0.0198), but not associated with molecular (sE-selectin) or functional (ankle-brachial index) markers of vascular health. (4) Conclusions: Our findings suggest that circulating sEPCR levels may be useful as biomarkers of endothelial dysfunction, including angiogenesis, in persons older than 35 years and that progressive loss of endothelial protein C receptors might be involved in the development and progression of PAD.

[1]  Abhijeet R. Sonawane,et al.  NLRP3 Inflammasome Activation in Peripheral Arterial Disease. , 2023, Journal of the American Heart Association.

[2]  J. Griffin,et al.  EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia , 2022, JCI insight.

[3]  U. Hedin,et al.  Circulating Biomarkers in Lower Extremity Artery Disease , 2022, European cardiology.

[4]  C. Ballantyne,et al.  Metabolic Inflammation and Insulin Resistance in Obesity , 2020, Circulation research.

[5]  F. Kronenberg,et al.  One simple claudication question as first step in Peripheral Arterial Disease (PAD) screening: A meta-analysis of the association with reduced Ankle Brachial Index (ABI) in 27,945 subjects , 2019, PloS one.

[6]  C. Kramer,et al.  A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease , 2019, Vascular medicine.

[7]  A. Bukowska,et al.  The endothelial status reflected by circulating endothelial cells, circulating endothelial progenitor cells and soluble thrombomodulin in patients with mild and resistant hypertension. , 2019, Vascular pharmacology.

[8]  C. Jackson,et al.  Activated protein C binds directly to Tie2: possible beneficial effects on endothelial barrier function , 2017, Cellular and Molecular Life Sciences.

[9]  M. Zwahlen,et al.  Endothelial progenitor cells as a biological marker of peripheral artery disease , 2016, Vascular medicine.

[10]  O. Jazaeri,et al.  Overview of Classification Systems in Peripheral Artery Disease , 2014, Seminars in Interventional Radiology.

[11]  Min‐Su Han,et al.  Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo. , 2014, Pharmacological research.

[12]  Jean S. Campbell,et al.  A disintegrin and metalloproteinase 17 regulates TNF and TNFR1 levels in inflammation and liver regeneration in mice. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[13]  Wenqiang Song,et al.  Supplementary information Figure S1 , 2013 .

[14]  C. Kırma,et al.  Soluble endothelial protein C receptor levels and protein C activity in patients with acute ST-segment elevation myocardial infarction , 2013, Coronary artery disease.

[15]  T. Münzel,et al.  Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease , 2012, Thrombosis and Haemostasis.

[16]  R. Schnabel,et al.  Multiple Endothelial Biomarkers and Noninvasive Vascular Function in the General Population: The Gutenberg Health Study , 2012, Hypertension.

[17]  M. Libra,et al.  Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. , 2012, Cytokine.

[18]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[19]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[20]  P. Chang,et al.  Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. , 2011, Cardiovascular research.

[21]  C. V. D. van der Kallen,et al.  The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study , 2011, European journal of clinical investigation.

[22]  Maria Blettner,et al.  Distribution and Categorization of Left Ventricular Measurements in the General Population: Results From the Population-Based Gutenberg Heart Study , 2010, Circulation. Cardiovascular imaging.

[23]  Sakae Tanaka,et al.  Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[24]  E. Feskens,et al.  Low‐grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study , 2009, European journal of clinical investigation.

[25]  P. Doevendans,et al.  Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. , 2009, Journal of the American College of Cardiology.

[26]  S. Blankenberg,et al.  Different Calculations of Ankle-Brachial Index and Their Impact on Cardiovascular Risk Prediction , 2008, Circulation.

[27]  B. Neel,et al.  Protein-tyrosine Phosphatase 1B Expression Is Induced by Inflammation in Vivo* , 2008, Journal of Biological Chemistry.

[28]  R. Schuepbach,et al.  Protective signaling pathways of activated protein C in endothelial cells. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[29]  G. Lip,et al.  Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. , 2007, Chest.

[30]  Y. Li,et al.  Role of ADAM17 in the ectodomain shedding of TNF‐α and its receptors by neutrophils and macrophages , 2007, Journal of leukocyte biology.

[31]  J. Griffin,et al.  The cytoprotective protein C pathway. , 2007 .

[32]  C. Esmon,et al.  Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor‐α converting enzyme/ADAM17 , 2007, Journal of thrombosis and haemostasis : JTH.

[33]  A. Avogaro,et al.  Number and Function of Endothelial Progenitor Cells as a Marker of Severity for Diabetic Vasculopathy , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[34]  E. Di Cera,et al.  Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells* , 2006, Journal of Biological Chemistry.

[35]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[36]  T. Suda,et al.  Activated Protein C Induces Endothelial Cell Proliferation by Mitogen-Activated Protein Kinase Activation In Vitro and Angiogenesis In Vivo , 2004, Circulation research.

[37]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[39]  Brian H Annex,et al.  Claudication of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Disease : A Phase II Randomized , Double-Blind , Controlled Study of Adenoviral Delivery Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial , 2003 .

[40]  E. Boerwinkle,et al.  Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease , 2003, Circulation.

[41]  M. Marron,et al.  The Antiinflammatory Endothelial Tyrosine Kinase Tie2 Interacts With a Novel Nuclear Factor-&kgr;B Inhibitor ABIN-2 , 2003, Circulation research.

[42]  C. Esmon,et al.  Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. , 2001, The American journal of pathology.

[43]  C. Esmon,et al.  Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. , 2000, Blood.

[44]  C. Esmon,et al.  Mechanisms by Which Soluble Endothelial Cell Protein C Receptor Modulates Protein C and Activated Protein C Function* , 2000, The Journal of Biological Chemistry.

[45]  C. Esmon,et al.  The Interaction between the Endothelial Cell Protein C Receptor and Protein C Is Dictated by the γ-Carboxyglutamic Acid Domain of Protein C* , 1997, The Journal of Biological Chemistry.

[46]  K. Miwa,et al.  Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. , 1997, Cardiovascular research.

[47]  C. McCollum,et al.  Prognostic value of increased soluble thrombomodulin and increased soluble E‐selectin in ischaemic heart disease , 1997, European journal of haematology.

[48]  C. Esmon,et al.  The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Amiral,et al.  Levels of plasma thrombomodulin are increased in atheromatous arterial disease. , 1993, Thrombosis research.

[50]  J. Neefjes,et al.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. , 1992, Immunology.

[51]  J. Onderwater,et al.  Evidence for endocytosis of E‐selectin in human endothelial cells , 1992, European journal of immunology.

[52]  C. Esmon,et al.  Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. , 1989, Blood.

[53]  M Trede,et al.  [Surgical treatment of peripheral circulation disorders]. , 1973, Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.